These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 21960651

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men.
    Lind L, Vessby B, Sundström J.
    Arterioscler Thromb Vasc Biol; 2006 Feb; 26(2):406-10. PubMed ID: 16306426
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study.
    Sattar N, Williams K, Sniderman AD, D'Agostino R, Haffner SM.
    Circulation; 2004 Oct 26; 110(17):2687-93. PubMed ID: 15492304
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men.
    Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B.
    Stroke; 2004 Oct 26; 35(10):2248-52. PubMed ID: 15345795
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The Apolipoprotein B/Apolipoprotein A 1 ratio in relation to metabolic syndrome and its components in a sample of the Tunisian population.
    Belfki H, Ben Ali S, Bougatef S, Ben Ahmed D, Haddad N, Jmal A, Abdennebi M, Ben Romdhane H.
    Exp Mol Pathol; 2011 Oct 26; 91(2):622-5. PubMed ID: 21801720
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The value of apolipoprotein B/A1 ratio in the diagnosis of metabolic syndrome in a Korean population.
    Jung CH, Hwang JY, Yu JH, Shin MS, Bae SJ, Park JY, Kim HK, Lee WJ.
    Clin Endocrinol (Oxf); 2012 Nov 26; 77(5):699-706. PubMed ID: 22211563
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of short- and long-term growth hormone replacement on lipoprotein composition and on very-low-density lipoprotein and low-density lipoprotein apolipoprotein B100 kinetics in growth hormone-deficient hypopituitary subjects.
    Kearney T, de Gallegos CN, Proudler A, Parker K, Anayaoku V, Bannister P, Venkatesan S, Johnston DG.
    Metabolism; 2003 Jan 26; 52(1):50-9. PubMed ID: 12524662
    [Abstract] [Full Text] [Related]

  • 18. Discordance between apolipoprotein B and low-density lipoprotein particle number is associated with insulin resistance in clinical practice.
    Varvel SA, Dayspring TD, Edmonds Y, Thiselton DL, Ghaedi L, Voros S, McConnell JP, Sasinowski M, Dall T, Warnick GR.
    J Clin Lipidol; 2015 Jan 26; 9(2):247-55. PubMed ID: 25911082
    [Abstract] [Full Text] [Related]

  • 19. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study.
    Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, D'Agostino RB, Vasan RS, Robins SJ.
    Circulation; 2006 Jan 03; 113(1):20-9. PubMed ID: 16380547
    [Abstract] [Full Text] [Related]

  • 20. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S, MIRACL Study Investigators.
    J Am Coll Cardiol; 2009 Jun 09; 53(23):2186-96. PubMed ID: 19497447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.